JP2018198596A5 - - Google Patents

Download PDF

Info

Publication number
JP2018198596A5
JP2018198596A5 JP2018128111A JP2018128111A JP2018198596A5 JP 2018198596 A5 JP2018198596 A5 JP 2018198596A5 JP 2018128111 A JP2018128111 A JP 2018128111A JP 2018128111 A JP2018128111 A JP 2018128111A JP 2018198596 A5 JP2018198596 A5 JP 2018198596A5
Authority
JP
Japan
Prior art keywords
pad4
antibody according
antibody
seq
pad4 antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018128111A
Other languages
English (en)
Japanese (ja)
Other versions
JP6675739B2 (ja
JP2018198596A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018198596A publication Critical patent/JP2018198596A/ja
Publication of JP2018198596A5 publication Critical patent/JP2018198596A5/ja
Application granted granted Critical
Publication of JP6675739B2 publication Critical patent/JP6675739B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018128111A 2015-03-06 2018-07-05 新規抗pad4抗体 Active JP6675739B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015044518 2015-03-06
JP2015044518 2015-03-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017505334A Division JP6369922B2 (ja) 2015-03-06 2016-03-07 新規抗pad4抗体

Publications (3)

Publication Number Publication Date
JP2018198596A JP2018198596A (ja) 2018-12-20
JP2018198596A5 true JP2018198596A5 (enExample) 2019-04-18
JP6675739B2 JP6675739B2 (ja) 2020-04-01

Family

ID=56880525

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017505334A Active JP6369922B2 (ja) 2015-03-06 2016-03-07 新規抗pad4抗体
JP2018128111A Active JP6675739B2 (ja) 2015-03-06 2018-07-05 新規抗pad4抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017505334A Active JP6369922B2 (ja) 2015-03-06 2016-03-07 新規抗pad4抗体

Country Status (5)

Country Link
US (3) US11447569B2 (enExample)
EP (2) EP4223786A3 (enExample)
JP (2) JP6369922B2 (enExample)
ES (1) ES2952132T3 (enExample)
WO (1) WO2016143753A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11447569B2 (en) 2015-03-06 2022-09-20 Public University Corporation Yokohama City University Anti-PAD4 antibody
JP7422069B2 (ja) 2017-09-19 2024-01-25 トロピック バイオサイエンシーズ ユーケー リミテッド 真核細胞において遺伝子発現をサイレンシングするための非コードrna分子の特異性の改変
WO2019131769A1 (ja) * 2017-12-26 2019-07-04 公立大学法人名古屋市立大学 新規抗pad4抗体
US11254736B2 (en) 2019-02-15 2022-02-22 Integral Molecular, Inc. Antibodies comprising a common light chain and uses thereof
CN119708241A (zh) 2019-02-15 2025-03-28 因特格尔莫来库乐有限公司 密封蛋白6抗体及其用途
CN111733151B (zh) * 2020-07-13 2021-11-12 山东新创生物科技有限公司 一种基于padi4作为肿瘤标志物制得的抗原、抗体及应用
WO2022035834A1 (en) * 2020-08-10 2022-02-17 Integral Molecular, Inc. Methods and compositions for making antibody libraries and antibodies isolated from the same
AR124914A1 (es) 2021-02-18 2023-05-17 Mitsubishi Tanabe Pharma Corp Nuevo anticuerpo anti-pad4
US20250003951A1 (en) * 2021-04-21 2025-01-02 Oxford University Innovation Limited Method and composition
EP4558529A1 (en) * 2022-07-22 2025-05-28 Bristol-Myers Squibb Company Antibodies binding to human pad4 and uses thereof
CN120282987A (zh) 2022-11-30 2025-07-08 因特格尔莫来库乐有限公司 包括双特异性型式的针对紧密连接蛋白6的抗体
AR131398A1 (es) 2022-12-19 2025-03-12 Astrazeneca Ab Tratamiento de enfermedades autoinmunitarias
WO2024233254A2 (en) * 2023-05-05 2024-11-14 The Johns Hopkins University Human monoclonal antibodies for treating subjects suffering from pulmonary fibrosis
WO2025024265A1 (en) 2023-07-21 2025-01-30 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad4 modulators
WO2025122927A1 (en) * 2023-12-06 2025-06-12 Integral Molecular, Inc. Antibodies directed to claudin 18.2, including bispecific formats thereof
AU2024406222A1 (en) 2023-12-20 2026-06-04 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rβ) and related methods
WO2026020127A2 (en) 2024-07-19 2026-01-22 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad2 modulators
WO2026136763A1 (en) 2024-12-19 2026-06-25 Bristol-Myers Squibb Company Genetic predictor for il18 driven disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP4304274B2 (ja) 2004-03-04 2009-07-29 国立大学法人広島大学 ニワトリ−ヒトキメラ抗体発現用ベクターおよびこれを用いたニワトリ−ヒトキメラ抗体生産方法、並びにその利用
US7745690B2 (en) 2004-03-09 2010-06-29 Nagoya Industrial Science Research Institute Transgenic nonhuman mammal representing the pathologic conditions of human rheumatoid arthritis
JP5252339B2 (ja) * 2007-12-25 2013-07-31 地方独立行政法人東京都健康長寿医療センター Pad4及び抗pad4抗体の測定方法並びに関節リウマチの検出方法
WO2011066372A2 (en) * 2009-11-25 2011-06-03 The Johns Hopkins University Citrullination of human peptidylarginine deiminase 4 (pad-4) regulates its function and immunogenicity
JPWO2012026309A1 (ja) 2010-08-23 2013-10-28 公立大学法人横浜市立大学 抗pad4抗体医薬の創成
WO2013143026A1 (en) 2012-03-31 2013-10-03 Abmart (Shanghai) Co., Ltd Peptide and antibody libraries and uses thereof
US11447569B2 (en) 2015-03-06 2022-09-20 Public University Corporation Yokohama City University Anti-PAD4 antibody
WO2016155745A1 (en) * 2015-03-27 2016-10-06 Rigshospitalet Cross-reactive anti-pad antibodies

Similar Documents

Publication Publication Date Title
JP2020501532A5 (enExample)
JP2017160222A5 (enExample)
JP2017113019A5 (enExample)
JP2018193386A5 (enExample)
JP2012526542A5 (enExample)
RU2015100656A (ru) Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения
RU2019118359A (ru) Антитело к cd73 человека
JP2019506841A5 (enExample)
JP2009531283A5 (enExample)
NZ713461A (en) Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
JP2016020389A5 (enExample)
JP2014518883A5 (enExample)
JP2019531093A5 (enExample)
RU2021114500A (ru) НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ
JP2012000112A5 (enExample)
JP2010516708A5 (enExample)
JP2022119899A5 (enExample)
HRP20230078T1 (hr) Sredstva za vezivanje vegf/dll4 i njihova uporaba
JP2013539454A5 (enExample)
JP2005120106A5 (enExample)
JP2015525208A5 (enExample)
JP2008525033A5 (enExample)
WO2009103105A3 (en) Mimotopes of alpha-synuclein and vaccines thereof for the treatment of neurodegenerative disorders
JP2013539369A5 (enExample)
EA200970694A1 (ru) ПЭГИЛИРОВАННЫЕ Fab-ФРАГМЕНТЫ АНТИТЕЛ К ПЕПТИДУ Aβ